MétaCan
Menu
Back to cohort
Record W4410621868 · doi:10.1093/europace/euaf085.499

Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis

2025· article· en· W4410621868 on OpenAlexafffund
Deborah Siegal, Jeff S. Healey, William F. McIntyre, David Conen, Michael R. Gold, Christopher B. Granger, Jens Cosedis Nielsen, Daniel Wojdyla, Renato D. Lópes

Bibliographic record

VenueEP Europace · 2025
Typearticle
Languageen
FieldMedicine
TopicAtrial Fibrillation Management and Outcomes
Canadian institutionsMcMaster UniversityUniversity of Ottawa
FundersPfizerCanadian Institutes of Health ResearchBristol-Myers Squibb
KeywordsApixabanAtrial fibrillationAspirinSubclinical infectionMedicineIncidence (geometry)Internal medicineCardiologyWarfarinRivaroxaban

Abstract

fetched live from OpenAlex

Abstract Background ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation) was a randomized double-blind, double-dummy trial which showed that apixaban, compared with aspirin, reduced stroke and systemic embolism, but increased major bleeding in patients aged ≥55 years with subclinical atrial fibrillation (AF) and CHA2DS2-VASc score ≥3. Objectives To characterize major bleeding events, determine the cumulative incidence of major bleeding (overall and by treatment, site, and severity), and determine risk factors associated with major bleeding. Study Design and Methods: We performed a pre-specified sub-analysis of major bleeding events defined as overt bleeding accompanied by a decrease in hemoglobin of ≥2 g/dL or transfusion of ≥2 units of packed red cells, occurring at a critical site, or resulting in death (International Society on Thrombosis and Haemostasis criteria) in the on-treatment population. Results After mean follow-up of 3.5 years, major bleeding occurred in 86/1989 patients on apixaban (1.71% per patient-year) and 47/1972 patients on aspirin (0.95% per patient-year) (HR 1.80; 95% CI, 1.26 to 2.57; p=0.001) (Table 1). Gastrointestinal bleeding was most common, representing 52.3% of bleeds in the apixaban group and 42.5% of bleeds in the aspirin group. The frequency of intracranial (0.6% vs. 0.8%, p=0.547) and fatal bleeding (0.3% vs. 0.2%, p=0.40) was low and similar between groups, while major gastrointestinal bleeding was more frequent in patients on apixaban (2.3% vs. 1.0%, p=0.002). The cumulative incidence of major bleeding is shown in Figure 1 according to randomized treatment, bleeding site and severity. Most bleeding events (73.8%) were not considered severe or fatal. Baseline covariates associated with an increased risk of major bleeding included ongoing cancer (HR 3.10, 95%CI 1.61-5.96), randomization to apixaban (HR 1.83, 95%CI 1.28-2.62), and age (HR 1.45, 95%CI 1.27-1.65, for each increase of 5 years). Conclusions The increased risk of major bleeding with apixaban is driven by gastrointestinal bleeding. Almost 75% of major bleeds were not considered emergencies and required only supportive measures. Increasing age and active cancer were associated with increased risk of major bleeding.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.393

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.320
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueEP EuropaceSame topicAtrial Fibrillation Management and OutcomesFrench-language works237,207